Abstract
Amiodarone is an iodine rich agent widely used for the treatment of ventricular arrhythmias, paroxysmal supraventricular tachycardia, atrial fibrillation and flutter. However 14-18% of patients treated with amiodarone develop overt thyroid dysfunction in the form of either amiodarone-induced thyrotoxicosis (AIT) or amiodaroneinduced hypothyroidism (AIH). Two different types of AIT have been recognised and designated as Type 1 and Type 2. Distinguishing between the two is often difficult, but necessary for instituting appropriate treatment. We report a case of a 56 year-old male patient who was started on amiodarone for atrial fibrillation and then developed AIT. The challenges in the diagnosis and management of these patients are discussed.
Article Type
Case Report
Publication Date
12-19-2009
First Page
319
Last Page
323
Creative Commons License

This work is licensed under a Creative Commons Attribution-No Derivative Works 4.0 International License.
Recommended Citation
PS, Sudheer Ahamed and Mathew, Abe
(2009)
"A Case of Amiodarone-Induced Thyrotoxicosis : A diagnostic and therapeutic dilemma,"
Sultan Qaboos University Medical Journal: Vol. 9: 319-323.
DOI: https://doi.org/10.18295/2075-0528.2808